RECKITT Benckiser (RB) has attracted some unwanted attention, with the Therapeutic Goods Administration confirming it is investigating complaints about advertising for its Nuromol ibuprofen/paracetamol combination analgesic.
News Limited has highlighted the complaints which relate to advertising for Nuromol on buses, promoting the fact that it can be purchased without prescription - in contrast to the now rescheduled codeine products such as Nurofen Plus.
A particular Nuromol advertisement included the wording "the alternative to codeine you've been waiting for", a potential breach of the Therapeutic Goods Act 1989 banning any reference to a Schedule 4 drug in a consumer advertisement.
The company has argued that the advertisement referencing codeine was only targeted to pharmacists and GP's for whom such advertising is within guidelines.
RB was fined $6 million in 2016 for misleading the public with its Nurofen "specific pain" marketing campaign, identifying four different "targeted" pain labels for identical products (PD 29 Apr 2016).
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Apr 18
